Methyl threo-12,13-dihydroxy-9(Z)-octadecenoate is a lipid.

Methyl linolenate-13C17 is an isotope-labeled fatty acid ester.

Methyl 3-chlorobicyclo[1.1.1]pentane-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

Mer/c-Met-IN-1 is a potent Mer/c-met dual inhibitor with IC50 values of 1 and 19 nM. Mer/c-Met-IN-1 can inhibit cancer cells proliferation, migration and induce apoptosis. Mer/c-Met-IN-1 can be used for the research of cancer, such as colon cancer.

Meglitinide is an ATP-sensitive potassium (KATP) channel inhibitor. Meglitinide exhibits IC50 values of 0.26 μM, 0.53 μM and 1.6 μM against KATP channels containing SUR1, SUR2A and SUR2B, respectively, with a Kd value of 7 μM for both SUR1 and SUR2A, and a Kd value of 8 μM for SUR2B. Meglitinide binds to the SUR1, SUR2A and SUR2B subunits with high affinity to close KATP channels, acting on a binding site shared by all SUR subtypes, and its interaction with SUR1 carrying the S1237Y mutation remains unchanged. Meglitinide is applicable to research related to type 2 diabetes.

MCULE-3064932370 is a covalent and allosteric SUMO E1 (heterodimer of Aos1 and Uba2) inhibitor with IC50 values ranging from 16.66 μM to 2.96 μM. MCULE-3064932370 inhibits SUMOylation of Uba2. MCULE-3064932370 has anti-cancer activity against breast cancer.

M2WJ332 is an inhibitor of the M2 proton channel of the influenza A virus M2S31N mutant M2. M2WJ332 potently inhibits the influenza A virus A/M2-S31N proton channel in Xenopus laevis oocytes, with an IC50 of 16 μM. M2WJ332 completely inhibits plaque formation by the influenza A virus carrying the M2S31N mutant. M2WJ332 is applicable to research related to influenza A virus infection.

LY580276 is an ATP-competitive ALK5 inhibitor with an IC50 of 175 nM. LY580276 inhibits transforming growth factor-β-induced epithelial-mesenchymal transition. LY580276 can be used for cancer research.

LY-326188 is a HIV-1 protease inhibitor, with an IC50 of 0.42 nM. LY326188 exhibits potent protection of HIV-1 infected cells.

LY164846 is an orally active cephalosporin. LY164846 is highly sensitive to Haemophilus influenzae (including Ampicillin-resistant strains) and Moraxella catarrhalis (with MIC90 ≤ 4 μg/mL). LY164846 is generally sensitive to Methicillin-resistant Staphylococcus aureus and Streptococcus (except Enterococcus) (with MIC90: 0.25 - 8 μg/mL), and moderately sensitive to anaerobic bacteria. LY164846 has MBC/MIC ratio to Haemophilus influenzae of ≤ 2, showing bactericidal activity. LY164846 can be used for research on respiratory and skin infections.

LTK-14A, a derivative of Garcinol, is a selective histone butyrylation inhibitor. LTK-14A does not affect acetylation. LTK-14A significantly inhibits the butyrylation of H4K5 and downregulated the expression of proadipogenic genes, thus culminating in abolished adipogenesis. LTK-14A can be used for the study of obesity.

LTD4 antagonist 3 (FK011 hydrochloride) is a LTD4 antagonist. LTD4 antagonist 3 has agonistic activity for PPAR-γ, with a fold-increase of 1.50 at 1 μM and 2.35 at 10 μM. LTD4 antagonist 3 can be used of development of non-steroidal anti-inflammatory drugs (NSAIDs).

LT-104A is a potent PDE4 inhibitor that elevates intracellular cAMP levels (EC50 = 1.9 μM) and inhibits PDE4D3 activity (IC50 = 9.3 μM). LT-104A activates the cAMP-PKA-CREB anti-inflammatory signaling pathway and suppresses NF-κB-related gene expression (Il1b and Nos2). LT-104A can be used for inflammation-related disease research.

LSD1-IN-41 (compound 7) is a potent and selective LSD1 inhibitor. LSD1-IN-41 can be used for diffuse intrinsic pontine glioma (DIPG) research when combined with HDAC inhibitors.

LPA1 receptor antagonist-7 is a LPA1 antagonist. LPA1 receptor antagonist-7 blocks downstream signaling pathways mediated by LPA1. LPA1 receptor antagonist-7 inhibits LPA-induced migration and invasion of cancer cells. LPA1 receptor antagonist-7 can be used for the research of triple-negative breast cancer.

LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC50 values of 1 nM and 3 nM against mouse and human ACSL5, and IC50 values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity.

Lirexapride is a 5-HT4/Dopamine D2 receptor agonist. Lirexapride stimulants gastrointestinal motor. Lirexapride can be used for research on digestive system disorders.

LGF308 is a PROTAC degrader of BRD4 that exhibits selective cytotoxicity toward cancer cells over normal cells. LGF308 mediates the formation of a ternary complex between BRD4 and DCAF11 to achieve BRD4 degradation. LGF308 induces tumor cell apoptosis by upregulating apoptosis-related proteins. LGF308 inhibits tumor cell proliferation and migration in breast cancer and triple-negative breast cancer cell lines. LGF308 can be used for the research of breast cancer.

Levomequitazine (Compound V0114) ((S)-Mequitazine), the levorotatory enantiomer of Mequitazine, is an orally active, inverse H4 receptor agonist (IC50s: 94 nM (hM2), 17 nM (hM3)). Levomequitazine strongly binds to human histamine H4 receptor. Levomequitazine antagonizes the activating action induced by histamine on H4 receptor. Levomequitazine induces a powerful and statistically significant anti-inflammatory effect. Levomequitazine can be used for research on inflammatory diseases.

Lenalidomide-CO-C7-NH2 is a CRBN-dependent intermediate of BET PROTAC degrader. Consisting of the E3 ubiquitin ligase ligand Lenalidomide conjugated with a PROTAC linker, Lenalidomide-CO-C7-NH2 induces the specific degradation of the oncoprotein BRD4. By depleting BRD4, Lenalidomide-CO-C7-NH2 effectively inhibits cancer cell proliferation, induces cell cycle arrest and promotes apoptosis, thereby exhibiting significant anti-tumor activity in xenograft models. Lenalidomide-CO-C7-NH2 serves as an important tool molecule for the study of acute myeloid leukemia.

LDLRAP1-IN-1 (Compound B19) is a LDLRAP1 inhibitor and antiviral agent, with an IC50 of 4.98 μM for disrupting the interaction between LDLRAP1 and LDLR. LDLRAP1-IN-1 covalently modifies the C119 residue of LDLRAP1 at the LDLRAP1-LDLR binding interface, thereby disrupting the interaction between LDLRAP1 and LDLR. LDLRAP1-IN-1 exhibits antiviral activity against HCoV-OC43.

LCK ligand-1 is a ligand targeting LCK, which serves as a target protein ligand for the synthesis of the PROTAC degrader SJ45566.

L-Arg-DSPE is an arginine-functionalized DSPE lipid containing free guanidine groups. L-Arg-DSPE serves as a component of NO-responsive degradable drug-loaded liposomal nanomotors (L-Arg@Lip-DOX), promoting drug deep tumor tissue penetration and cellular internalization. L-Arg-DSPE can be used for the research of drug delivery.

L-797591 hydrochloride is a selective sst1 agonist. L-797591 hydrochloride mimicks the effects of SRIF-14 and SRIF-28 by potently inhibiting either Forskolin-stimulated or CRH-stimulated cAMP accumulation.

L-652343 is a dual cyclooxygenase/lipoxygenase inhibitor. L-652343 can inhibit the production of LTB4 in isolated human polymorphonuclear leukocytes treated with Calcimycin (IC50: 1.4 μM), but it is inactive in whole blood. L-652343 can be used in the research of inflammatory and immune diseases.

L-367773 is an orally active, selective oxytocin receptor antagonist, with Ki values of 26 nM and 61 nM for rat uterine oxytocin receptor and human uterine oxytocin receptor, respectively. L-367773 inhibits Oxytocin-stimulated uterine contractions.

KW-2170 hydrochloride is an alkylating agent and topoisomerase II inhibitor. KW-2170 hydrochloride stabilizes the topoisomerase II-DNA complex, causing DNA double-strand breaks, thereby preventing DNA replication and transcription, and ultimately leading to the death of tumor cells. KW-2170 hydrochloride exhibits potent and broad-spectrum anti-tumor activity in various mouse and human tumor models. KW-2170 hydrochloride can be used in the research of solid tumors.

KRAS G12D-IN-34 (Compound 13) is a KRAS (G12D) inhibitor with IC50 values for KRAS (G12D) and KRAS (WT) of 1.05 nM and 1.59 μM respectively. KRAS G12D-IN-34 can be used for research on non-small cell lung cancer.

KRAS G12C-IN-78 is a selective SWII-binding KRASG12C dual inhibitor targeting both inactive and active states. KRAS G12C-IN-78 rapidly inhibits ERK1/2 phosphorylation, induces covalent adduct formation with endogenous KRASG12C, suppresses MAPK pathway gene expression, and inhibits cellular proliferation in KRASG12C mutant cells. KRAS G12C-IN-78 can be used for the research of KRASG12C mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer.

KP-1212 is a nucleoside. KP-1212 exerts its antiviral effect by mutagenizing the viral genome. KP-1212 inhibits HIV growth.